FSD Pharma $HUGE FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need
FSD Pharma is a life sciences holding company dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services. The Company is currently advancing a pipeline of innovative therapeutics that target “Total Brain Health” with multiple lead clinical candidates addressing a variety of neurodegenerative and neuropsychiatric diseases.
FSD Pharma has the following 3 drug candidates in its pipeline:
- Lucid-PSYCH: a unique psychedelic molecule currently undergoing IND-enabling studies with a targeted treatment for neuropsychiatric disorders, such as Major Depressive Disorder.
- Lucid-MS: a patented, proprietary neuroprotective new chemical entity (NCE) that has demonstrated in preclinical models the potential to reverse and prevent myelin degradation, an underlying cause of Multiple Sclerosis and other neurodegenerative orders.
- FSD-PEA: an ultra-micro-PEA compound with the potential to address a range of inflammatory conditions. FSD-PEA has completed phase-1 FDA approved trials with positive topline results, and indications for phase-2 are currently being evaluated.